Mammotome Launches Two Innovative Products to Advance Breast Health in China
Danaher
Product Design and Manufacturer
ShanghaiJune 22, 2022PR Newswire -- On June 18, during the 2022 China-U.S. Breast Cancer Summit, Mammotome, the global leader in breast biopsy and minimally invasive surgery, announced two new products.--MammotometmDisposable Breast Biopsy Needle and RevolvetmEX Bidirectional Vacuum-Assisted Breast Biopsy and Excision System Officially Launched.Mammotome, as a leader in the breast health industry, is also a member of the Danaher Group.With the reliable quality and innovative design of these two new products, Mammotome will more efficiently assist Chinese medical professionals in addressing complex breast biopsies and minimally invasive surgeries, protecting the breast health of Chinese women.
Mammotome Launches Two New Products -- LiXuan Disposable Breast Biopsy and Excision Needle and Revolve(tm) EX Dual-Direction Vacuum-Assisted Breast Biopsy and Excision System
At the new product launch event, Professor Zhi-Min Shao from the Fudan University-affiliated Cancer Hospital delivered the opening speech. Professor Ning Liao, Director of the Breast Surgery Department at Guangdong Provincial People's Hospital, attended the launch ceremony and delivered a speech reviewing the 20-year development of breast minimally invasive rotary cutting technology in China. Dr. Murawa from the University Hospital of Zielona Góra in Poland shared via video the application of VAE&VAB technology in Europe. The new product launch event was held in Guangzhou as the main venue, with five sub-venues in Shenyang, Suzhou, Changsha, Zhengzhou, and Ganzhou linked together. Experts in the field of breast diseases from both international and Chinese communities jointly witnessed the launch of Mammotome’s new product.
Mammotome Revolve(tm) Disposable Breast Biopsy Needle Officially Launched
MammotometmThe Disposable Breast Biopsy Needle is the first product designed and manufactured by Mammotome in China, holding significant importance for Mammotome's localization strategy. In Li Xuan...tmDuring the development process, Mammotome has gathered a large-scale, professional, and strong Chinese local innovative R&D team. Based on Mammotome's self-developed system and relying on global technical strength, they have deeply understood the needs of Chinese doctors and patients, and created this innovative product with a craftsman spirit. Its local factory applies high-standard production processes, equipped with a 100,000-level clean workshop, to timely meet the needs of local doctors and patients with high-quality "Made in China."
Mammotome Revolve(tm) EX Bidirectional Vacuum-Assisted Breast Biopsy and Excision System Officially Launched
Mammotome RevolvetmEX Bidirectional Vacuum-Assisted Breast Biopsy and Excision System is the upgraded flagship product of the new generation Mammotome. RevolvetmEX adopts the latest generation of bidirectional vacuum system, equipped with a 3+1 sample management collection system, which significantly improves the sampling speed, enhances surgical efficiency, shortens operation time for patients, and also helps improve the bed turnover rate in hospitals.
Relying on the "special access, pilot first" preferential policies of Boao Lecheng Pilot Zone in Hainan and the strong collaboration between Hainan Provincial People's Hospital and Hainan Boao Yiling Medical Consortium, Mammotome Revolve EX successfully conducted the world’s first surgery at Lecheng on March 18, 2021. During the product registration process, Mammotome utilized clinical data from surgeries performed in Lecheng as well as expert advice provided by the lead surgeon, successfully gaining approval from the National Medical Products Administration (NMPA) to complete the registration and market launch of the imported product.
"Building on a legacy of excellence, Mammotome converges dual strengths. The simultaneous launch of two new products in China exemplifies Mammotome's dedication to serving Chinese patients and healthcare providers with precision. It represents the powerful integration of our global technological expertise and local production advantages. Mammotome will always remain committed to delivering reliable products efficiently to our Chinese customers, safeguarding women’s health through innovative technology," said Qian Zhongjun, General Manager of Mammotome China. "Mammotome’s products and technologies have been accompanying the growth of China’s breast health initiatives for over two decades."In the future,Mammotome will deeply participate in and promote the development of breast health in China under the layout of Danaher's "Create and Elevate China" localization strategy, contributing to "Healthy China"!